Soluble B7-H1: Differences in Production Between Dendritic Cells and T Cells

Overview

Journal Immunol Lett

Specialty Allergy & Immunology

Date 2011 Dec 6

PMID 22138406

Citations 85

Authors

Xavier Frigola

Brant A Inman

Christopher J Krco

Xin Liu

Susan M Harrington

Peggy A Bulur

Allan B Dietz

Haidong Dong

Eugene D Kwon

Affiliations

Soon will be listed here.

Abstract

Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.

Citing Articles

Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis.

Wu Y, Zhang Y Ann Med. 2025; 57(1):2458236.

PMID: 39928126 PMC: 11812115. DOI: 10.1080/07853890.2025.2458236.

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.

Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C Nature. 2025; 639(8054):474-482.

PMID: 39910301 PMC: 11903305. DOI: 10.1038/s41586-024-08507-5.

PD-1 immunology in the kidneys: a growing relationship.

Chen R, Lin Q, Tang H, Dai X, Jiang L, Cui N Front Immunol. 2024; 15:1458209.

PMID: 39507530 PMC: 11537962. DOI: 10.3389/fimmu.2024.1458209.

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.

Lu Y, Jin Y, Liu F, Wang Z, Zhou W, Zhang Y Cancer Immunol Immunother. 2024; 73(11):220.

PMID: 39235609 PMC: 11377375. DOI: 10.1007/s00262-024-03796-1.

Exploring the dynamics of Programmed Death-Ligand 1 in canine lymphoma: unraveling mRNA amount, surface membrane expression and plasmatic levels.

Ubiali A, Conti L, DallAra P, De Maria R, Aresu L, Moretti P Front Vet Sci. 2024; 11:1412227.

PMID: 39132435 PMC: 11310028. DOI: 10.3389/fvets.2024.1412227.

References

Sica G, Choi I, Zhu G, Tamada K, Wang S, Tamura H . B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003; 18(6):849-61. DOI: 10.1016/s1074-7613(03)00152-3. View

Simon I, Liu Y, Krall K, Urban N, Wolfert R, Kim N . Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007; 106(1):112-8. DOI: 10.1016/j.ygyno.2007.03.007. View

Chapoval A, Ni J, Lau J, Wilcox R, Flies D, Liu D . B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001; 2(3):269-74. DOI: 10.1038/85339. View

Thompson R, Gillett M, Cheville J, Lohse C, Dong H, Webster W . Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004; 101(49):17174-9. PMC: 534606. DOI: 10.1073/pnas.0406351101. View

Simon I, Zhuo S, Corral L, Diamandis E, Sarno M, Wolfert R . B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006; 66(3):1570-5. DOI: 10.1158/0008-5472.CAN-04-3550. View

Azuma T, Yao S, Zhu G, Flies A, Flies S, Chen L . B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008; 111(7):3635-43. PMC: 2275025. DOI: 10.1182/blood-2007-11-123141. View

Her M, Kim D, Oh M, Jeong H, Choi I . Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus. 2009; 18(6):501-7. DOI: 10.1177/0961203308099176. View

Thompson R, Zang X, Lohse C, Leibovich B, Slovin S, Reuter V . Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008; 68(15):6054-8. PMC: 2918370. DOI: 10.1158/0008-5472.CAN-08-0869. View

Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison J . B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003; 100(18):10388-92. PMC: 193571. DOI: 10.1073/pnas.1434299100. View

10.

Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

11.

Krambeck A, Thompson R, Dong H, Lohse C, Park E, Kuntz S . B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006; 103(27):10391-10396. PMC: 1502468. DOI: 10.1073/pnas.0600937103. View

12.

Flies D, Chen L . The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007; 30(3):251-60. DOI: 10.1097/CJI.0b013e31802e085a. View

13.

Inman B, Frigola X, Harris K, Kuntz S, Lohse C, Leibovich B . Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol. 2008; 180(5):3578-84. PMC: 2792739. DOI: 10.4049/jimmunol.180.5.3578. View

14.

Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R . Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011; 17(7):1915-23. PMC: 3241002. DOI: 10.1158/1078-0432.CCR-10-0250. View

15.

Inman B, Frigola X, Dong H, Kwon E . Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007; 7(1):15-30. DOI: 10.2174/156800907780006878. View

16.

Wan B, Nie H, Liu A, Feng G, He D, Xu R . Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006; 177(12):8844-50. DOI: 10.4049/jimmunol.177.12.8844. View

17.

Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X . Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 2008; 123(4):538-46. PMC: 2433324. DOI: 10.1111/j.1365-2567.2007.02723.x. View

18.

Roth T, Sheinin Y, Lohse C, Kuntz S, Frigola X, Inman B . B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007; 67(16):7893-900. DOI: 10.1158/0008-5472.CAN-07-1068. View